Fermenta Biotech Ltd. carries a market capitalization of 10.87B, placing it among publicly traded companies globally. Its enterprise value stands at 9.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.87B |
| Enterprise Value | 9.40B |
Fermenta Biotech Ltd. currently has 28.67M shares outstanding.
| Shares Outstanding | 28.67M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Fermenta Biotech Ltd. trades at a trailing price-to-earnings ratio of 12.77. The price-to-sales ratio is 1.76, and the price-to-book ratio stands at 64.64.
| PE Ratio | 12.77 |
| PS Ratio | 1.76 |
| PB Ratio | 64.64 |
| P/TBV Ratio | 2.35 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, Fermenta Biotech Ltd. trades at an EV/EBITDA multiple of 12.03 and an EV/FCF ratio of 111.14. The EV/Sales ratio of 1.79 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.03 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.79 |
| EV / EBITDA | 12.03 |
| EV / EBIT | 12.03 |
| EV / FCF | 111.14 |
Fermenta Biotech Ltd. maintains a current ratio of 1.86, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.29, indicating elevated leverage, while an interest coverage ratio of 6.77 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.86 |
| Quick Ratio | 0.45 |
| Debt / Equity | 28.29 |
| Debt / EBITDA | 1.45 |
| Interest Coverage | 6.77 |
Fermenta Biotech Ltd. posts a return on equity of 40.97 and a return on invested capital of 11.52.
| Return on Equity (ROE) | 40.97 |
| Return on Assets (ROA) | 11.50 |
| Return on Invested Capital (ROIC) | 11.52 |
| Return on Capital Employed (ROCE) | 29.11 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.35 |
Over the trailing twelve months, Fermenta Biotech Ltd. has paid 256.06M in income taxes, reflecting an effective tax rate of 26.71.
| Income Tax | 256.06M |
| Effective Tax Rate | 26.71 |
Fermenta Biotech Ltd.'s stock has gained approximately 15.55217% over the past 52 weeks. The 50-day moving average sits at 318.39, while the 200-day moving average is 316.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | 15.55217% |
| 50-Day Moving Average | 318.39 |
| 200-Day Moving Average | 316.56 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Fermenta Biotech Ltd. generated 5.25B in revenue and converted that into 725.83M in net income, yielding earnings per share of 24.05. EBITDA reached 781.37M, while operating income came in at 781.37M.
| Revenue | 5.25B |
| Gross Profit | 3.38B |
| Operating Income | 781.37M |
| Pretax Income | 958.61M |
| Net Income | 725.83M |
| EBITDA | 781.37M |
| EBIT | 781.37M |
| Earnings Per Share (EPS) | 24.05 |
Fermenta Biotech Ltd. holds 945.91M in cash and equivalents against 1.13B in total debt, resulting in a net debt position of 771.91M. Total book value stands at 143.35M, with working capital of 1.79B providing operational flexibility.
| Cash & Cash Equivalents | 945.91M |
| Total Debt | 1.13B |
| Net Debt | 771.91M |
| Equity (Book Value) | 143.35M |
| Book Value Per Share | 4.94 |
| Working Capital | 1.79B |
Fermenta Biotech Ltd. operates with a gross margin of 64.42, reflecting its pricing power and cost economics. The operating margin of 14.87 and net profit margin of 13.81 provide insight into operational efficiency.
| Gross Margin | 64.42 |
| Operating Margin | 14.87 |
| Pretax Margin | 18.24 |
| Profit Margin | 13.81 |
| EBITDA Margin | 14.87 |
Fermenta Biotech Ltd.'s most recent stock split took place on February 13, 2020 with a 1:3 split ratio.
| Last Split Date | 2/13/2020 |
| Split Ratio | 1:3 |
Fermenta Biotech Ltd. posts an Altman Z-Score of 3.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.80 |